“…It is easier and safer to apply in clinical cohorts than experimental hypercapnia, breath-holding and drug interventions (Keyeux et al, 1995; Rostrup et al, 1996, 1994; Wagerle and Mishra, 1988). RSFA is sensitive to cerebrovascular and cardiovascular differences in ageing (Garrett et al, 2017; Tsvetanov et al, 2020b, 2015), small vessel disease (Makedonov et al, 2013), stroke (Nair et al, 2017; Raut et al, 2016), Alzheimer’s disease (Makedonov et al, 2016; Millar et al, 2020a), cognitive performance (Liu et al, 2021; Millar et al, 2021, 2020b) and the presence of brain tumours (Agarwal et al, 2019, 2017).…”